Trial Profile
A Prospective, Multicentre, Open Label, Non-Controlled, Observational, 26-Week Study in Patients Using NovoMix 30 (Biphasic Insulin Aspart 30) or Levemir (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Macedonia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2014
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin detemir (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 14 Aug 2014 Actual patient number was changed from 1462 to 3421, according to the ClinicalTrials.gov record.
- 09 Jun 2011 Actual end date changed from Sep 2010 to Oct 2010 as reported by ClinicalTrials.gov.
- 09 Jun 2011 Actual initiation date changed from Jun 2009 to May 2009 as reported by ClinicalTrials.gov.